Pay in 4 interest-free payments of $6.74 Learn more
Ships within 48 hours Β· Estimated delivery Aug 13 - Aug 18
This suggests that AOD 9604 may potentially augment the anti-cancer potency of doxorubicin while possibly minimizing unintended actions associated with non-target tissue exposure
While the peptide demonstrated a favorable safety profile, its development as a prescription obesity medication was discontinued in 2007 after mixed efficacy results in larger trials
Clinical trials
That's exactly why it belongs in a supervised program, not a self-experiment
Book your appointment below or speak with our pharmacist about whether B12 injections are right for you
The results were expressed in micromoles per deciliter and reported as changes from the baseline values
US$ 27.04
US$ 27.02
US$ 23.76
